Anebulo Pharmaceuticals, Inc.
ANEB evidence brief
What we can confirm
- Market Cap:
- $13.5M
What it means
What to watch
Prepared research question
What matters most for ANEB—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ANEB
Anebulo Pharmaceuticals, Inc. (ANEB) is a clinical-stage biopharmaceutical company developing novel solutions for acute cannabis-induced toxic effects, with its lead candidate selonabant (formerly ANEB-001) in Phase 1/2 trials.
Key risk: Early-stage pipeline
Market Cap
$13.5M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Dec 31, 2025.
Tracking 2 clinical trials for Anebulo Pharmaceuticals, Inc..
Anebulo Pharmaceuticals, Inc. (ANEB) is a clinical-stage biopharmaceutical company developing novel solutions for acute cannabis-induced toxic effects, with its lead candidate selonabant (formerly ANEB-001) in Phase 1/2 trials.
- Lead candidate selonabant (formerly ANEB-001) is a potent, small molecule antagonist of cannabinoid binding receptor type-1 (CB1) in Phase 2 for healthy volunteers [pipeline].
- First subjects dosed in Phase 1 single ascending dose study of intravenous selonabant in healthy young adults, supported by a collaborative grant from the National Institute on Drug Abuse (NIDA) [news · published 2025-09-25].
- Cash & equivalents of $9.0M as of 2025-12-31 [sec]; net income of -$2.0M for the same period [sec].
- Company announced intent to commence a cash tender offer at $3.50/share for up to 300K shares as part of a plan to go private [news · published 2025-12-22].
- Global cannabis use disorder market projected to grow significantly from 2025 to 2035, with Anebulo's ANEB-001 listed among investigational therapies [news · published 2026-09-18].
What works
- Selonabant is a potent, small molecule antagonist of CB1 receptor, targeting a specific mechanism for acute cannabis-induced toxicity [pipeline].
- Phase 1 study is supported by a collaborative grant from the National Institute on Drug Abuse (NIDA), indicating external validation [news · published 2025-09-25].
- Company has cash & equivalents of $9.0M as of 2025-12-31, providing near-term operational runway [sec].
What to weigh
- Company reported a net loss of -$2.0M for the period ending 2025-12-31 [sec].
- Selonabant is still in early clinical stages (Phase 1/2) with no approved products, implying significant development risk [pipeline].
- Company is pursuing a plan to go private via a cash tender offer, which may indicate challenges in public market valuation or financing [news · published 2025-12-22].
- Competitive landscape includes 43 competitors, many with similar or more advanced programs [pipeline].
From the filings
Quoted directly from source documents.
Selonabant is a CB1 receptor antagonist in Phase 2 for healthy volunteers.
“Pipeline Candidate: selonabant (formerly ANEB-001) Generic Name: selonabant Indication: Healthy Volunteers Phase: Phase 2 Mechanism of Action: Potent, small molecule antagonist of cannabinoid binding receptor type-1 (CB1)”
Pipeline
Catalyst timeline
- 2025-09-22 · Phase 1 Start of intravenous selonabant SAD study — Phase 1, randomized, double-blind, placebo-controlled, single ascending dose study in healthy adults aged 18-30 years.
Risks & what to watch (4)›
Key risks
- Early-stage pipeline — Selonabant is in Phase 1/2; no approved products, high clinical and regulatory risk [pipeline].
- Net loss and cash burn — Net loss of -$2.0M for period ending 2025-12-31; cash of $9.0M may fund limited operations [sec].
- Going-private plan — Plan to go private via tender offer may signal difficulty in raising public capital or achieving milestones [news · published 2025-12-22].
- Intense competition — 43 competitors in the space, many with similar or more advanced programs [pipeline].
What to watch
- Progress of Phase 1 SAD study of intravenous selonabant and initiation of Phase 2 [news · published 2025-09-25].
- Outcome of the cash tender offer and going-private process [news · published 2025-12-22].
- Financial reports for subsequent quarters to assess cash runway and net loss trends [sec].
- Market developments in cannabis use disorder treatment and competitive landscape [news · published 2026-09-18].
Sources: Catalysts · Competitor trials · News · Pipeline · Generated October 9, 2026 · How we verify sources →
Run Anebulo Pharmaceuticals, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Anebulo Pharmaceuticals, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Regulatory
Financials
Short Interest
as of Apr 21, 2026- % of float
- 2.2%
- Days to cover
- 1.5
- Shares short
- 146,372
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ANEB short interestGovernance
Frequently asked questions
What is the AI investment thesis for Anebulo Pharmaceuticals, Inc.?
Anebulo Pharmaceuticals, Inc. (ANEB) is a clinical-stage biopharmaceutical company developing novel solutions for acute cannabis-induced toxic effects, with its lead candidate selonabant (formerly ANEB-001) in Phase 1/2 trials.
Who is the CEO of Anebulo Pharmaceuticals, Inc.?
Mr. Richard Anthony Cunningham is the chief executive officer of Anebulo Pharmaceuticals, Inc. (ANEB).
Where is Anebulo Pharmaceuticals, Inc. headquartered?
Anebulo Pharmaceuticals, Inc. (ANEB) is headquartered in Lakeway, TX, United States.
What therapeutic areas does Anebulo Pharmaceuticals, Inc. focus on?
Anebulo Pharmaceuticals, Inc. develops therapies across Neurology, Metabolic.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.